Clinical and histologic characteristics of the independent set of patients with PTX3 serum evaluation
| BPH (n = 61) | Prostate cancer (n = 56) | P | |
|---|---|---|---|
| Age, y | 61.5 ± 10.4 | 65.6 ± 6.6 | 0.2 |
| Suspicious DRE (%) | 29.5 | 37.5 | 0.4 |
| Prostate volume (mL) | 59.3 ± 20.9 | 55.9 ± 13.8 | 0.7 |
| Total PSA levels (ng/mL) | 7.5 ± 3.7 | 8.3 ± 4.4 | 0.7 |
| PSA density (ng/mL*mL) | 0.4 ± 0.1 | 0.7 ± 0.3 | 0.5 |
| International Prostate Symptom Score (I-PSS) | 10.8 ± 8.1 | 13.1 ± 9.6 | 0.6 |
| Flow max (mL/s) | 15.0 ± 9.3 | 11.7 ± 7.3 | 0.1 |
| Post-void residual (mL) | 42.3 ± 21.5 | 33.0 ± 18.7 | 0.7 |
| Histologic grading of prostatic inflammation (G≥2) | 15/61 (24.5%) | 18/56 (34.1%) | 0.6 |
| Aggressiveness of prostatic inflammation (A≥2) | 9/61 (14.7%) | 11/56 (19.6%) | 0.4 |
| Biopsy Gleason score | |||
| ≤6 | 35 (62.5%) | ||
| 7 | 13 (23.2%) | ||
| ≥8 | 8 (14.3%) | ||